MT 2021 press wires

All news about ALNYLAM PHARMACEUTICALS, INC.

Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
Sales 2021 816 million

Net income 2021 -766 million

Net cash position 2021 1,321 million

PER 2021 ratio -30.2x
Yield 2021
Capitalization 23,244 million
23,244 million
VE / Sales 2021 26.9x
VE / Sales 2022 17.7x
Number of employees 1,453
Free float 99.4%

Chart ALNYLAM PHARMACEUTICALS, INC.
Duration :

Period :

Alnylam Pharmaceuticals, Inc. Technical Analysis Chart |  MarketScreener

Technical Analysis Trends ALNYLAM PHARMACEUTICALS, INC.

Short term Mid Road Long term
Tendencies Bullish Neutral Neutral

Evolution of the income statement

To sell

To buy

Average consensus SURPASS
Number of analysts 22
Last closing price

$ 194.35

Average price target

$ 205.81

Spread / Average target 5.90%